Guardant Health delivered an outstanding fourth quarter in 2025, with total revenue increasing by 39% to $281.3 million. This growth was primarily fueled by strong performance in oncology and screening, with oncology revenue up 30% and screening revenue significantly increasing due to 38,000 Shield screening tests. The company also improved its non-GAAP gross margin to 66% and reduced its free cash flow burn for the full year.

Guardant Health delivered an exceptional third quarter in 2025, achieving a 39% increase in total revenue to $265.2 million, driven by robust performance in oncology test volumes, significant growth in screening revenue from Shield, and solid contributions from biopharma and data. The company also improved its non-GAAP gross margin to 66% and reduced its net loss compared to the prior year, demonstrating strong operational execution and market expansion.

Guardant Health delivered an exceptional second quarter in 2025, with total revenue increasing by 31% year-over-year to $232.1 million, driven by robust performance in Oncology, Screening, and Biopharma & Data segments. The company also raised its full-year 2025 revenue guidance, reflecting continued strong demand and operational execution.

Guardant Health reported strong revenue growth of 21% in Q1 2025, driven by solid performance in oncology, screening, and biopharma & data segments. The company also increased its full-year 2025 revenue guidance.

Guardant Health reported Q4 2024 revenue of $201.8 million, a 30% year-over-year increase, driven by strong growth in precision oncology testing. The company reduced net loss compared to the prior year and continued to expand its product portfolio and partnerships.

Guardant Health reported a 34% increase in revenue for Q3 2024, reaching $191.5 million, driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds. The company raised its 2024 annual revenue guidance to $720 to $725 million and improved its free cash flow to $(55) million. Shield received favorable Medicare pricing of $920.

Guardant Health reported a strong second quarter with a 29% increase in revenue, driven by growth in clinical and biopharma testing volume and improved reimbursement for Guardant360. The FDA approved Shield as a first-line CRC screening option, and the company raised its full-year revenue guidance for 2024.

Guardant Health reported a strong first quarter with revenue of $168.5 million, a 31% increase year-over-year. The company saw growth in both clinical and biopharma testing volume and improved free cash flow. They also raised their 2024 annual revenue guidance to $675 to $685 million.

Guardant Health reported a 22% increase in revenue for Q4 2023, reaching $155.1 million, driven by growth in clinical and biopharmaceutical testing volumes. The company is progressing with FDA submissions for its Shield IVD test and anticipates a pivotal year for its screening business in 2024.

Guardant Health reported a 22% increase in revenue for Q3 2023, driven by strong clinical volume growth. The company has raised its full year 2023 revenue guidance to $553 to $556 million.

Guardant Health reported a strong second quarter in 2023, with revenue reaching $137.2 million, a 26% increase compared to the same period in 2022. The growth was primarily driven by a 49% increase in clinical testing volume. The company has raised its full-year 2023 revenue guidance to $545 to $550 million.

Guardant Health reported a strong start to 2023 with a 34% increase in revenue compared to Q1 2022, driven by significant growth in clinical testing volume. The company has raised its full-year revenue guidance and is making strides in CRC screening with its Shield test.

Guardant Health reported a 17% increase in revenue for Q4 2022 compared to Q4 2021, driven by growth in clinical and biopharma testing volumes. The company also highlighted advancements in its screening portfolio, including the ECLIPSE study for colorectal cancer detection.

Guardant Health reported revenue of $117.4 million for the third quarter of 2022, a 24% increase compared to the same period in 2021. The growth was primarily driven by a 42% increase in clinical testing volume and a 40% increase in biopharma sample volume. The company also made progress on the ECLIPSE study and the Shield LDT screening test.

Guardant Health reported strong Q2 2022 financial results, with revenue reaching $109.1 million, a 19% increase compared to the previous year. The company saw significant growth in clinical and biopharma testing volumes, and received Medicare coverage for Guardant Reveal™.

Guardant Health reported a 22% increase in revenue for the first quarter of 2022, driven by significant growth in clinical and biopharma testing volumes. The company launched its Shield LDT screening test and expanded partnerships, while also receiving regulatory approvals and Medicare coverage for key tests.

Guardant Health reported a 38% increase in revenue for Q4 2021, driven by growth in clinical testing and development services. The company also highlighted progress in its ECLIPSE and SHIELD studies and finalized a settlement with Foundation Medicine.

Guardant Health reported a 27% increase in revenue for the third quarter of 2021, reaching $94.8 million. The company saw significant growth in clinical and biopharma test volumes, despite the continued impact of COVID-19. However, the net loss also increased to $107.5 million, or $1.06 per share.

Guardant Health reported a revenue of $92.1 million for the second quarter of 2021, a 39% increase compared to the same period in 2020. The company saw growth in clinical and biopharmaceutical tests, and expanded its product portfolio.

Guardant Health reported a revenue of $78.7 million for the first quarter of 2021, a 17% increase compared to the corresponding period in 2020. The company launched Guardant Reveal and saw growth in clinical testing revenue, though it experienced a net loss of $109.7 million.

Guardant Health reported a 25% increase in revenue for the fourth quarter of 2020, reaching $78.3 million. The growth was primarily driven by a 47% increase in clinical testing revenue and a 148% increase in development services revenue. However, the company experienced a net loss of $93.7 million, or $0.94 per share, compared to a net loss of $25.2 million, or $0.27 per share, in the same period of the previous year.

Guardant Health reported a strong third quarter with a 23% increase in revenue compared to the corresponding period of 2019. The company also received FDA approval for Guardant360® CDx and launched an enhanced version of Guardant360.

Guardant Health reported a 23% increase in revenue for the second quarter of 2020, driven by growth in both precision oncology and development services. The company's cash position was strengthened by a public offering, ending the quarter with $1.1 billion in cash, cash equivalents and marketable securities.

Guardant Health reported an 84% increase in revenue for Q1 2020 compared to the prior year period, driven by growth in precision oncology testing. However, due to the uncertainty caused by the COVID-19 pandemic, the company withdrew its previously announced annual revenue and net loss guidance for 2020.

Guardant Health reported a strong fourth quarter and full year 2019, with Q4 revenue reaching $62.9 million, a 91% increase year-over-year. The company's full year revenue grew by 137% compared to 2018. They also provided full year 2020 revenue guidance of $275.0 million to $285.0 million.